Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer

References

• Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289–93.
   PubMed Web of Science ®Google Scholar
• Holmäng S, Hedelin H, Anderström C, Johansson SL. Long-term followup of all patients with muscle-invasive (stages T2, T3 and T4) bladder carcinoma in a geographical region. J Urol 1997;158:389–92.
   PubMed Web of Science ®Google Scholar
• Prout GRJr, Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979;43:2532–9.
   PubMed Web of Science ®Google Scholar
• Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24:296–304.
   PubMed Web of Science ®Google Scholar
• Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456–66.
   PubMed Web of Science ®Google Scholar
• Sherif A, De La Torre M, Malmstrom PU, Thorn M. Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. J Urol 2001;166:812–15.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Chebil G, Davidsson T, Gudjonsson S, Månsson W. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol 2006;175:84–8.
   PubMed Web of Science ®Google Scholar
• Sherif A, Garske U, de La Torre M, Thörn M. Hybrid SPECT-CT – an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 2006;50:83–91.
   PubMed Web of Science ®Google Scholar
• Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1–27.
   PubMed Web of Science ®Google Scholar
• Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018–23.
   PubMed Web of Science ®Google Scholar
• Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother 2008;31:34–42.
   PubMed Web of Science ®Google Scholar
• Marits P, Karlsson M, Sherif A, Garske U, Thörn M, Winqvist O. Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. Eur Urol 2006;49:59–70.
   PubMed Web of Science ®Google Scholar
• Dahl K, Karlsson M, Marits P, Hoffstedt A, Winqvist O, Thörn M. Metinel node – the first lymph node draining a metastasis – contains tumor-reactive lymphocytes. Ann Surg Oncol 2008;15:1454–63.
   PubMed Web of Science ®Google Scholar
• Karlsson M, Marits P, Dahl K, Dagöö T, Enerbäck S, Thörn M, et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol 2010;17:1747–57.
   PubMed Web of Science ®Google Scholar
• Sherif A, Hasan MN, Marits P, Karlsson M, Winqvist O, Thörn M. Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. Eur Urol 2010;58:105–11.
   PubMed Web of Science ®Google Scholar
• Antony PA, Piccirillo CA, Akpinarli A Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T-helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591–601.
   PubMed Web of Science ®Google Scholar
• Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, Ehst BD, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88–93.
   PubMed Web of Science ®Google Scholar
• Surman DR, Dudley ME, Overwijk WW, Restifo NP. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol 2000;164:562–5.
   PubMed Web of Science ®Google Scholar
• Marits P, Karlsson M, Dahl K Larsson P, Wanders A, Thörn M, et al. Sentinel node lymphocytes: tumor reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer 2006;94:1478–84.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009–18.
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration (ABC). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:202–6.
   PubMed Web of Science ®Google Scholar
• Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, et al. Nordic Urothelial Cancer Group. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004;45:297–303.
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullén A, Nilsson S, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 2012;61:1229–38.
   PubMed Web of Science ®Google Scholar
• Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2–4): an autopsy study on 367 patients. Urol Int 1999;62:69–75.
   PubMed Web of Science ®Google Scholar
• Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010;57:641–7.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4.
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer Immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344:641–5.
   PubMed Web of Science ®Google Scholar
• Mishra A, Shiozawa Y, Pienta KJ, Taichman RS. Homing of cancer cells to the bone. Cancer Microenviron 2011;4:221–35.
   PubMedGoogle Scholar
• Wierda D, Pazdernik TL. Toxicity of platinum complexes on hemopoietic precursor cells. J Pharmacol Exp Ther 1979;211:531–8.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen YT, Song HZ, Chun Huang GC, Chen LB. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 2011;17:3002–11.
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011;121:3100–8.
   PubMed Web of Science ®Google Scholar
• Hu J, Kinn J, Zirakzadeh AA, Sherif A, Norstedt G, Wikström AC, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol 2013;172:490–9.
   PubMed Web of Science ®Google Scholar